(Total Views: 915)
Posted On: 08/15/2017 6:32:51 PM
Post# of 72446
I refuted FrozenChao's first soft bashing post with ease.
Your estimate would be correct for a psoriasis drug which the stock dropped 25% after its Phase 2 result. Dr. Reddy agreed to a $490M deal with $47.5M upfront for XenoPort's aforementioned drug, XP23829.
"Shares of Santa Clara, CA-based XenoPort were down 25 percent by midmorning Tuesday after the company announced positive preliminary results from a Phase 2 clinical trial of its oral psoriasis drug."
https://www.dddmag.com/news/2015/09/xenoport-...dy-results
"Dr. Reddy's Laboratories ($RDY) has signed a $490 million drug licensing deal with California's XenoPort ($XNPT) as the struggling biotech looks to shed its R&D ahead of a rumored sale of the company."
http://www.fiercebiotech.com/r-d/under-pressu...dr-reddy-s
Your estimate would be correct for a psoriasis drug which the stock dropped 25% after its Phase 2 result. Dr. Reddy agreed to a $490M deal with $47.5M upfront for XenoPort's aforementioned drug, XP23829.
"Shares of Santa Clara, CA-based XenoPort were down 25 percent by midmorning Tuesday after the company announced positive preliminary results from a Phase 2 clinical trial of its oral psoriasis drug."
https://www.dddmag.com/news/2015/09/xenoport-...dy-results
"Dr. Reddy's Laboratories ($RDY) has signed a $490 million drug licensing deal with California's XenoPort ($XNPT) as the struggling biotech looks to shed its R&D ahead of a rumored sale of the company."
http://www.fiercebiotech.com/r-d/under-pressu...dr-reddy-s
Quote:
Purisol at best is worth $300-$600M as a pharma deal. Most likely $40-$60M upfront with backend royalties.
(1)
(0)
